14 results about "Tauopathy" patented technology

Binding reagents for tau protein variants, including antibodies that bind to tau protein, and uses thereof are disclosed. The uses include determining if a patient has or is at risk of developing a tauopathy, and treating a patient having a tauopathy.

Methods of differentiating and quantifying modifications in the tau protein in bio-fluids to detect, classify, and treat a plurality of tauopathies are disclosed. The disclosed methods include liquid chromatographic mass spectrometric analyses on isolated tau protein fragments to identify and quantify deamidated or isomerized asparagines or aspartic acids indicative of a neuropathology associated with a tauopathy.

The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an alpha-2A adrenergic receptor (ADRA2A) gene, as well as methods of inhibiting expression of an ADRA2A gene and methods of treating subjects having an ADRA2A-associated disease or disorder, e.g., a primary tauopathy or Alzheimer's disease, using such dsRNAi agents and compositions.

A non-invasive device for detecting Alzheimer's Disease-associated pathologies, comprising a fundus camera comprising a spectral reflectance imaging unit that includes a broadband light source and a light sensor and a lens assembly to focus light from the broadband light source onto a fundus of an eye, and one or more processors to detect reflected and / or backscattered light from the eye, illuminated by the broadband light source, using the light sensor for determining spectral reflectance information, generate a plurality of spectral reflectance maps comprising counts of reflected and / or backscattered light at a different wavelength or a different range of wavelengths, assign a weight to each of the spectral reflectance maps, and determine one or more regions of interest from the weighted spectral reflectance maps as being a potential Alzheimer's Disease-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy.

The present invention relates to a novel heteroaryl-carbohydrazone acyldinitrile compound in which a saturated heterocyclic ring is substituted or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition for preventing or treating nervous system diseases comprising the same as an active ingredient. The heteroaryl-carbohydrazone acyldinitrile compound with a substituted saturated heterocyclic ring according to the present invention can effectively inhibit the aggregation or excessive phosphorylation of Tau protein and / or TDP-43, thereby being useful in the prevention or treatment of nervous system diseases including Tau disease and TDP-43 proteopathy.

The disclosure relates to formulations of double stranded ribonucleic acid (dsRNAi) agents targeting a MAPT gene, as well as methods of inhibiting expression of a MAPT gene and methods of treating subjects having a MAPT-associated neurodegenerative disease or disorder, e.g., Alzheimer's disease, FTD, PSP, or other tauopathy, using such dsRNAi agent formulations.

The present invention relates to regions within the synaptogyrin-3 RNA sequence that are targetable by oligonucleotide inhibitors, such as antisense oligonucleotides. Specifically, these synaptogyrin-3 inhibitors are provided for general pharmaceutical use and for treating or inhibiting the progression of tauopathy or the symptoms of tauopathy.

Provided herein is a method of identifying a pre-stage neurofibrillary tangle (NFT) in a patient sample, including obtaining a sample from a patient suspected of having or at risk of developing a tauopathy, incubating the sample with a composition comprising a first binding reagent, wherein the first binding reagent is specific to Ser262 and / or Ser356 of a tau protein, and detecting binding between the first binding reagent and the tau protein, wherein detecting binding between the first binding reagent and the tau protein indicates the presence of a pre-stage NFT in the patient sample.

Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.

The present invention provides a tau-binding antibody or antigen-binding fragment thereof for use in a method of treating a tauopathy in a human subject in need thereof, the method comprising administering to the human subject at least one dose of 30 mg / kg to 120 mg / kg of the tau-binding antibody or binding fragment thereof, wherein the tau-binding antibody or binding fragment thereof comprises: a light chain variable region comprising a CDR1 selected from SEQ ID No.: 1, a CDR2 selected from SEQ ID No.: 2, and a CDR3 selected from SEQ ID No.: 3; and a heavy chain variable region comprising a CDR1 selected from SEQ ID No.: 4, a CDR2 selected from SEQ ID No.: 5, and a CDR3 selected from SEQ ID No.: 6. In various embodiments, the human subject has a low tau burden or is not an APOE4 carrier.

The present application relates to the technical field of molecular biology, and particularly relates to a deer horn stem cell exosome-derived miRNA and its use in anti-inflammatory, antioxidant, and collagen and elastin synthesis promotion. The present application performs small RNA sequencing analysis on deer horn stem cell exosomes, systematically identifies the characteristic high-abundance miRNA composition, and clearly defines the use of some specific miRNAs (such as hsa-miR-92a-3p, hsa-miR-451a, hsa-let-7b-5p, and chi-miR-191-5p) in anti-inflammatory, antioxidant, and collagen and elastin synthesis promotion, thereby providing clear and verifiable technical support for the application of the miRNAs in anti-inflammatory preparations, tissue repair materials, and functional skin care products.

It has been established that increased levels of lactylated of tau protein in the brain and CNS is associated with tauopathies and neurodegenerative diseases, and increased levels of lactylated lysine on tau protein has been established as a marked for AD. Compositions and methods for the detection and treatments of tauopathies have been developed. In some forms, the methods identify and quantify lactylated lysine on tau protein in a biological sample from a subject to diagnose a tauopathy, such as AD. In some forms, the methods identify a subject as having or at risk of having a tauopathy. In some forms, the methods include treating the tauopathy. Compositions to identify a tauopathy include lactylated tau binders, such as antibodies are also described. Compositions to treat or prevent a tauopathy, such as lactylated tau peptides having a defined lactyllysine, are also described.

The present disclosure provides monoclonal antibodies that selectively bind to pathological tau over native tau. In certain aspects, the antibodies inhibit or minimize propagation of tau aggregates and / or reduce spread of pathological tau in vivo. In other aspects, the disclosure comprises a method of treating, ameliorating, and / or preventing a tauopathy in a subject, comprising administering any one of the antibodies of the disclosure to the subject. In yet other aspects, the disclosure comprises methods of detecting pathological tau using any one of the antibodies of the disclosure.

Methods for preventing or treating brain neuronal diseases are provided. The methods include administering mesenchymal stem cells having increased agouti-related peptide (AgRP) expression or a conditioned medium thereof to a subject in need thereof. In some embodiments, the conditioned medium contains AgRP. The methods may further comprise administering ghrelin. The brain neuronal diseases include Alzheimer's disease, frontotemporal dementia, tauopathy, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, stroke, thrombosis, embolism, head trauma, cerebral circulatory or metabolic disorders, brain dysfunction, and dementia.